Predictors of premature withdrawal and dose reduction in patients with chronic hepatitis C treated with Peginterferon alfa-2a (40kD) plus ribavirin in a large, multinational, open-label expanded access program.

LEE, Samuel; Stuart ROBERTS; Hanna BERAK; Geoffrey DUSHEIKO; Hugh HARLEY; Edward GANE and Petr HUSA. Predictors of premature withdrawal and dose reduction in patients with chronic hepatitis C treated with Peginterferon alfa-2a (40kD) plus ribavirin in a large, multinational, open-label expanded access program. (Predikce předčasného vysazení a redukce dávky PEG-IFN alfa-2a a ribavirinu u nemocných s chronickou hepatitidou C.). Hepatology. Philadelphia: Saunders, 2009, vol. 50, No 4, p. 717A, 1 pp. ISSN 0270-9139.

Basic information

Original name

Predictors of premature withdrawal and dose reduction in patients with chronic hepatitis C treated with Peginterferon alfa-2a (40kD) plus ribavirin in a large, multinational, open-label expanded access program.

Authors

LEE, Samuel; Stuart ROBERTS; Hanna BERAK; Geoffrey DUSHEIKO; Hugh HARLEY; Edward GANE and Petr HUSA

Edition

Hepatology, Philadelphia, Saunders, 2009, 0270-9139

---

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30300 3.3 Health sciences

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 10.840

Organization unit

Faculty of Medicine

UT WoS

000270456000875

Tags

International impact, Reviewed